NCT01847638View on ClinicalTrials.gov

Prolensa (Bromfenac) 0.07% QD vs. Ilevro (Nepafenac) 0.3% QD for Treatment of Ocular Inflammation Post Cataract Surgery

NACompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

April 1, 2013

Primary Completion Date

July 16, 2016

Study Completion Date

August 23, 2018

Conditions
CataractRetinal EdemaInflammation
Interventions
DRUG

Prolensa (bromfenac 0.07%)

Comparison of Prolensa (bromfenac ophthalmic solution) 0.07% QD vs. Ilevro (nepafenac ophthalmic suspension) 0.3% QD for Treatment of Ocular Inflammation Associated with Cataract Surgery

DRUG

Ilevro (nepafenac 0.3%)

Comparison of Prolensa (bromfenac ophthalmic solution) 0.07% QD vs. Ilevro (nepafenac ophthalmic suspension) 0.3% QD for Treatment of Ocular Inflammation Associated with Cataract Surgery

Trial Locations (1)

37203

Toyos Clinic, Nashville

All Listed Sponsors
collaborator

Bausch & Lomb Incorporated

INDUSTRY

lead

Melissa Toyos

OTHER

NCT01847638 - Prolensa (Bromfenac) 0.07% QD vs. Ilevro (Nepafenac) 0.3% QD for Treatment of Ocular Inflammation Post Cataract Surgery | Biotech Hunter | Biotech Hunter